Lee DH, et al. - Researchers evaluated the impact of cilostazol (CTZ; an antiplatelet agent with many beneficial metabolic effects via inhibition of phosphodiesterase-3 in vascular smooth muscle cells, cardiomyocytes, adipose tissue, and platelets) vs aspirin in this study with Korean diabetic patients who have subclinical coronary atherosclerosis. For this investigation, 100 patients with diabetes and mild-to-moderate coronary atherosclerosis were randomized to groups of either 200-mg/day CTZ or 100-mg/day aspirin (n=50 each). Only in the CTZ group were observed increases in HDL-cholesterol, decreases in triglyceride, liver enzyme, and hsCRP levels, and decreases in abdominal visceral fat and insulin resistance. According to this prospective study, 12 months of CTZ treatment decreased stenosis of the coronary artery and the noncalcified plaque component. In patients with diabetes, CTZ treatment could be an option for preventing the progression of coronary atherosclerosis.